Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
about
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingPathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell VaccinationCurrent status of immunotherapyPathways and therapeutic targets in melanomaRegulatory T Cell Modulation by CBP/EP300 Bromodomain InhibitionCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyFriend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphomaDose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.iPSC-Derived Regulatory Dendritic Cells Inhibit Allograft Rejection by Generating Alloantigen-Specific Regulatory T Cells.Molecular Signatures of Human Regulatory T Cells in Colorectal Cancer and Polyps.Human IL-6RhiTIGIT- CD4+CD127lowCD25+ T cells display potent in vitro suppressive capacity and a distinct Th17 profile.A novel and effective method to generate human porcine-specific regulatory T cells with high expression of IL-10, TGF-β1 and IL-35Stromal reengineering to treat pancreas cancerRapid rebound of the Treg compartment in DEREG mice limits the impact of Treg depletion on mycobacterial burden, but prevents autoimmunityThe role of chemoattractant receptors in shaping the tumor microenvironment.Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection.Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunityBeyond adjuvants: immunomodulation strategies to enhance T cell immunitySialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humansEndometriosis-induced changes in regulatory T cells - insights towards developing permanent contraception.CD4+ T cells in aged or thymectomized recipients of allogeneic stem cell transplantations.Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients.Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma.Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion.Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in miceLocal production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma.Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse modelActivation and Recruitment of Regulatory T Cells via Chemokine Receptor Activation in Trichinella spiralis-Infected Mice.Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responsesInstability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunityOvercoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineCCL22 to Activate Treg Migration and Suppress Depigmentation in VitiligoFecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut.Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinomaThe intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.
P2860
Q26742012-C91A11C0-918D-48FA-A2FD-6EB3FE05AE67Q26765345-63CF7E56-EE29-40F0-B0EA-A7C2F156BFECQ26773314-1CAEFE6D-EF72-4C66-8354-E7DB616C5977Q26865736-664ADE29-4B70-4BD5-B9F9-640B1B261D32Q27644651-B7D9453F-2A7A-4A72-BC9B-CB5F79E3A84FQ28066199-AA43E697-AF1A-4963-A593-490A354D420BQ28072320-889EA13C-2011-4C8B-B230-FE4AC62CBA03Q33420837-38A58DAC-7F5B-45C7-BE27-7AFAB50F6A51Q33659263-421F4957-B364-48B2-8710-2D1B757A4C14Q33736438-1BD9FC89-5B7D-48F2-9013-FCD97D21930BQ33800947-33AE2B97-8AB3-43E3-9046-604B69438804Q33822472-AF504289-F009-4E36-9429-A5FE84B43725Q33827708-E8243BB5-68E1-438E-99EE-B83A3C9F6017Q33933431-4E3C6A85-4D89-40DB-AD95-757E9A729290Q33993124-4BB5C11A-F0A8-4271-8903-D04D2FF8B4CBQ34089124-949515F2-5E54-474A-9130-DD94D8C68671Q34855293-FB5238B6-3319-4644-A9A5-695F8CB785E6Q35224581-DBAC0D0A-F351-4CBE-A1DC-1836EE77C0BEQ35666506-CDD0E6F7-42CA-4E4F-9108-7162C9659F25Q35740445-6DBEE574-2335-4308-851B-9CE2D2AC2EA3Q35864618-AB82F7D5-A22A-414D-AC79-B4AD3E42D14EQ35888837-ED428B70-0382-48BD-84FD-92CEFAB89BFDQ35993123-D054EE71-BF44-4076-9CDF-6650A43AECD5Q36011105-CE2FB72C-8F97-4311-8FA4-85C1B42A6394Q36027105-EBD7E850-E638-4726-B6F2-722485D2EE47Q36107928-7FC50BA8-AAA1-46B2-86B3-0C13349ACD47Q36132344-7F89B8EE-DF0A-4A44-ABC0-01EBEC0320ACQ36212905-3E8258A1-9CAE-4E55-BA37-666B1085D3F3Q36413088-93106173-0CB7-4597-9A76-9143FCA9CBCCQ36821149-395B6B08-2B8A-4063-9ED7-53B4866B4057Q36911858-691C0F32-8AD6-4421-8256-90A1E522316EQ36972226-87536A38-52F6-4BCE-A424-320264D24AB1Q36978175-C9CBFCB7-EB32-43F2-A04C-C51C5A3C5E10Q37017190-7D074E31-C292-4AC8-ACFC-C3A6E314F4A1Q37162527-F0EA0511-F90C-47A9-B67C-BF37776ABA06Q37224420-376F923E-9B23-47B2-AE10-35CE190EDE37Q37299737-2429FFBB-D0EC-4CF9-93A3-2E917E82524FQ37376599-B689EAE0-6077-403A-AE4A-30D61C0E6FB0Q37437275-011A690F-7EA5-438D-89F3-980AAEFE0D46Q37518395-ED1936FC-005C-4A95-A11D-258C76F02994
P2860
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-CCR4 mAb selectively depl ...... or immune responses in humans.
@en
Anti-CCR4 mAb selectively depl ...... or immune responses in humans.
@nl
type
label
Anti-CCR4 mAb selectively depl ...... or immune responses in humans.
@en
Anti-CCR4 mAb selectively depl ...... or immune responses in humans.
@nl
prefLabel
Anti-CCR4 mAb selectively depl ...... or immune responses in humans.
@en
Anti-CCR4 mAb selectively depl ...... or immune responses in humans.
@nl
P2093
P2860
P356
P1476
Anti-CCR4 mAb selectively depl ...... mor immune responses in humans
@en
P2093
Atsushi Tanemura
Eiichi Sato
Elke Jäger
Hiroyoshi Nishikawa
Ichiro Katayama
Julia Karbach
Megumi Nishioka
Sachiko Ezoe
Shimon Sakaguchi
Yasuo Fukumori
P2860
P304
17945-17950
P356
10.1073/PNAS.1316796110
P407
P577
2013-10-14T00:00:00Z